Intermediate Syndrome Following Organophosphate Insecticide Poisoning  by Yang, Chen-Chang & Deng, Jou-Fang
J Chin Med Assoc • November 2007 • Vol 70 • No 11 467
© 2007 Elsevier. All rights reserved.
Introduction
Pesticide poisonings remain a serious public health
problem worldwide. According to the World Health
Organization’s estimate, 3 million cases of pesticide
poisoning occur every year, resulting in more than
250,000 deaths.1 This number also accounts for a
substantial fraction of the almost 900,000 people
worldwide who die by suicide every year. Among the
numerous pesticides that can result in death,
organophosphate insecticides are the most common
culprit agents because of their high toxicity.
Acute organophosphate insecticide poisoning can
manifest 3 different phases of toxic effects, namely,
acute cholinergic crisis, intermediate syndrome (IMS),
and delayed polyneuropathy.2–5 Acute cholinergic crisis
develops within a few minutes to several hours after
exposure, and affects peripheral muscarinic and nicotinic
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receptors, as well as the central nervous system,
through the inhibition of carboxylic esterase enzymes,
of which acetylcholinesterase is the most clinically
important. Typical manifestations of cholinergic crisis
include, but are not limited to, nausea, vomiting, diar-
rhea, abdominal cramp, urinary incontinence, miosis,
salivation, lacrimation, bronchorrhea, bradycardia,
hypotension, fasciculation, muscle paralysis, dizziness,
confusion, seizures, coma, and respiratory failure. Death
can occur within a very short space of time if life-
threatening conditions, such as respiratory failure, are
not treated promptly and appropriately.
Organophosphate-related delayed neurotoxic
effect, which is commonly referred to as organophos-
phate-induced delayed neurotoxicity (OPIDN), occurs
2–3 weeks after acute exposure to certain organophos-
phate insecticides.2 The clinical features are predomi-
nantly motor neuropathy and primarily manifest as
numbness and weakness of the lower extremities, fol-
lowed by progressive ascending weakness of limb mus-
cles.2,5 The disease entity is believed to be due to the
inhibition of a poorly characterized esterase called the
neuropathy target esterase.5
In addition to acute cholinergic crisis and delayed
neurotoxicity, organophosphate insecticides can cause
IMS as well. The term IMS was first described by
Senanayake and Karalliedde in 1987 because it arose
in the interval between the end of the acute cholinergic
crisis and the onset of OPIDN.2 According to that
report, IMS was characterized by weakness of proximal
limb muscles, neck flexors, respiratory muscles, and
motor cranial nerves, and was attributed to muscle fiber
necrosis following acute cholinergic crisis. Numerous
studies have been published following Senanayake and
Karalliedde’s report, and the incidence of IMS has
been reported to be as high as 80%.6–14 Although
the incidence of IMS may be high and the syndrome
has been considered a major contributing factor of
organophosphate-related morbidity and mortality, the
pathophysiology that underlies IMS remains unclear.
Illustrative Cases
Case 1
A 26-year-old male attempted to commit suicide by
ingesting an unknown amount of an unnamed pesti-
cide. He was found lying next to a farm field with clear
consciousness and marked weakness. He was sent to a
local hospital, where gastric lavage, activated charcoal,
and Fuller’s earth were given because the patient stated
that he probably had taken paraquat. He was then
referred to our toxicological service.
On arrival, his vital signs were as follows: blood pres-
sure 138/82 mmHg, pulse 90/min, respiratory rate
18/min, and temperature 36.4°C. Physical examina-
tion revealed the presence of coma, pinpoint pupil,
salivation and bronchorrhea. Urine sodium dithionite
test for paraquat was negative. Laboratory data were
remarkable for potassium 3.1mmol/L (reference range,
3.4–4.7 mmol/L), amylase 309 U/L (reference range,
0–190 U/L), and white blood cell count 18,500/mm3
(reference range, 4,500–11,000/mm3). Because organ-
ophosphate intoxication with impending respiratory
failure was highly suspected, he was intubated with
assisted ventilation. Moreover, he was treated with
atropine and pralidoxime, and was admitted to the
intensive care unit. Initial red blood cell (RBC) cho-
linesterase level was 14 UKAT/L (reference range,
20–46 UKAT/L), and plasma cholinesterase level was
1 UKAT/L (reference range, 20–61 UKAT/L).
On day 2, the patient was clear without respiratory
distress, bronchial secretion, or muscle weakness, al-
though the creatinine phosphokinase level had increased
to 1,956 U/L (reference range, 27–168 U/L). The
culprit pesticide was later identified to be methami-
dophos rather than parathion or paraquat. The doses
of atropine and pralidoxime were gradually tapered and
finally discontinued on the morning of day 3. Weaning
from the ventilator was successfully performed, and he
was transferred to the general ward. He remained symp-
tomless and did not manifest obvious muscle weakness
until the night of that day, when he was noted to
develop confusion, followed by deep coma. Physical
examination was remarkable for unresponsiveness, flac-
cid extremities, decreased deep tendon reflexes, shal-
low respiration, and dilated pupils. His breathing sound
was clear and pulse oximetry monitoring showed nor-
mal oxygen saturation with 2 L/min oxygen supple-
ment. Arterial blood gas analysis nevertheless revealed
hypercapnia with PCO2 of 96 mmHg. IMS was diag-
nosed and he was reintubated. After ventilatory sup-
port for another 6 days, he was smoothly extubated and
was discharged uneventfully on day 12. Both atropine
and pralidoxime were not administered during the
second course of artificial ventilation.
Case 2
A 33-year-old previously healthy policeman attempted
suicide by ingesting 4–5 mouthfuls of methami-
dophos. He was found comatose in his bedroom and
was sent to a local hospital, where asystole was noted on
arrival. Cardiopulmonary resuscitation was immediately
instituted, and he regained his vital signs. He was
treated with atropine 1 mg and pralidoxime 2 g, and
was referred to our toxicological service.
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On arrival, the patient was in a deep coma, with a
Glasgow Coma Score of E1VTM1. Physical examination
revealed the presence of pinpoint pupil, hypotension,
tachycardia, chemical conjunctivitis, cold sweating,
and garlic-like odor. Laboratory data were remarkable
for white blood cell count 22,100/mm3, creatinine
1.5 mg/dL (reference range, 0.7–1.5 mg/dL), glucose
182 mg/dL (reference range, 65–115 mg/dL), arte-
rial pH 7.23, PCO2 36 mmHg, PO2 214 mmHg,
HCO3 14.6 mmol/L, RBC cholinesterase 3 UKAT/L,
and plasma cholinesterase 1 UKAT/L. Routine toxi-
cological screen was negative for other drugs or tox-
ins. Electrocardiography showed sinus tachycardia
and left anterior hemiblock. Computed tomography
of the brain was unyielding for hypoxic or traumatic
insult. The patient was treated with vigorous fluid
replacement as well as continuous infusion of atropine
10 mg/day and pralidoxime 12 g/day, and was then
admitted to the intensive care unit.
On day 2, he was clear and his breathing sound was
clear. His pupils were 2 mm in diameter with prompt
light reflex. However, he appeared weak and was unable
to flex his neck or abduct his shoulders, although the
muscle power of his distal limbs was within normal
limits. Treatment with atropine and pralidoxime was
continued and his muscle power gradually improved
to full strength. He was successfully weaned on day 4
and was transferred to the general ward on day 5. The
RBC and plasma cholinesterase level improved to
35 UKAT/L and 5 UKAT/L, respectively, on that day.
The patient’s remaining hospitalization course was
fairly uneventful except for transient mild atelectasis
of the left lower lung. On day 9, he was discharged
with normal levels of RBC and plasma cholinesterase
(45 UKAT/L and 23 UKAT/L, respectively). He
developed OPIDN 3 weeks after the toxic exposure and
continued to manifest mild weakness of all extremities
1 year later.
Mechanisms
IMS is well recognized as a disorder of the neuro-
muscular junction; however, its exact underlying
mechanisms are not clearly defined. Senanayake and
Karalliedde in their first report of IMS suggested that
the syndrome might be caused by pathologic changes
in the postsynaptic end-plate region of striated muscles
because such lesions were described in experimental
animals (hens and rats) that developed a similar pattern
of paralysis after organophosphate insecticide poison-
ing.2 Eyer, in a review paper, supported the aforemen-
tioned hypothesis and proposed that myonecrosis was
mediated by calcium mobilization in the muscle fibers.3
Several researchers stated that oxidative cellular damage
to muscle membranes could be another possible mech-
anism of muscle necrosis.9,11 Clinically, John et al
demonstrated an association between increased blood
muscle enzymes (i.e. creatinine phosphokinase and
lactate dehydrogenase) and the development of IMS,
which also supported the role of muscle injury in IMS.10
On the contrary, it was found in a prospective study
of 19 patients with organophosphate poisoning that
muscle fiber necrosis was unlikely to be the etiology of
IMS because muscle biopsy specimens in patients with
IMS showed a few necrotic fibers only.5,6,16 This led
to the proposition that IMS was a combined pre- and
postsynaptic impairment of neuromuscular transmission
as evidenced by electromyographic observations, and
that IMS occurred after prolonged and severe acetyl-
cholinesterase inhibition.6,15 Benson and McIntire,
however, did not agree and suggested that either dif-
ferent susceptibility of various cholinergic receptors or
inadequate oxime therapy played a role in the devel-
opment of IMS if IMS did exist.17 Baker and Sedgwick,
in a single fiber electromyographic study of patients
voluntarily exposed to sarin, found reversible subclini-
cal changes compatible with the development of non-
depolarizing neuromuscular block.18 They stated that
IMS could be explained by the above findings, which
were due to a reduction in the number of functioning
acetylcholinesterase receptors at the postjunctional
membrane or a failure of acetylcholine release. In 1997,
Sedgwick and Senanayake further proposed that down-
regulation or desensitization of postsynaptic acetylcho-
line receptors after prolonged acetylcholine stimulation
could explain the occurrence of IMS.19
Clinical Features
Following exposure to various organophosphate insec-
ticides, clinical manifestations of IMS typically occur
within 24 to 96 hours, and affect conscious patients
without fasciculation or other cholinergic signs.2
Marked weakness of neck flexion and varying degree of
proximal limb muscle weakness, manifesting as weak-
ness of shoulder abduction and hip flexion, are the
constant clinical features. Respiratory insufficiency is
also common and frequently draws medical attention
to the onset of the syndrome. Other possible manifes-
tations are involvement of muscles innervated by motor
cranial nerves and decreased deep tendon reflexes.
Sensory impairment is not a clinical manifestation of
IMS. With appropriate therapy, recovery from IMS
occurs 5–18 days after the onset of weakness. According
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to the report by Senanayake and Karalliedde, the
regression of toxic signs among patients who survived
IMS followed a distinct pattern.2 Muscle power first
resumed in cranial nerve-innervated muscles, followed
by respiratory muscles, proximal muscles, and neck
flexors.
Patients with atypical manifestations of IMS, espe-
cially a relapse or a continuum of acute cholinergic cri-
sis, however, were frequently reported in the literature
and were included in many clinical studies of IMS.6,7,15
For example, De Bleecker et al, in a prospective study
of 19 patients with organophosphate poisoning, iden-
tified 8 patients with IMS, 6 of them had relapsing
cholinergic signs, such as lacrimation, increased
bronchial and salivary secretion, diarrhea, sweating,
bradycardia, and fasciculation, that superimposed on
IMS.6 He et al studied 21 IMS cases, 3 of whom actu-
ally showed rebounding of acute cholinergic crisis prior
to the development of IMS.7 Moreover, the onset of
IMS in that study ranged between 7 and 75 hours
post-exposure, and lasted between 6 and 30 days.
Because the definition of IMS differed across
studies, reports on its incidence varied accordingly. In
the first report of IMS, 10 out of 92 patients with
organophosphate poisoning developed IMS, which
yielded an incidence of 11%.2 The reported incidence of
IMS ranges from 7.7% to as high as 84% (Table 1).6–14
Findings on the risk factors of IMS also differed
among studies. Although IMS generally occurred
among patients with prolonged and severe inhibition
of acetylcholinesterase,6,15 not every patient with severe
inhibition of the enzyme developed IMS.10,11 There
were other risk factors of IMS as well, including delayed
metabolism of organophosphates due to toxicokinetic
factors of the insecticides or impaired organ function,
severity of poisoning, elevated muscle enzymes, and
inadequate or late oxime therapy (Table 1).6,9–11,13,16,17
IMS has also been linked preferentially to patients’
exposure to specific organophosphates, namely fen-
thion, dimethoate and monocrotophos, all of which are
dimethoxy compounds.2 However, IMS was not limited
to patients with exposure to these organophosphates.
Parathion, combined ethylparathion and methyl-
parathion, methamidophos, dichlorvos, and various
other organophosphate insecticides have all been impli-
cated in the development of IMS.4,6,7,11–15,20
Electrophysiologic Findings
Electrophysiologic study has been proposed as a spe-
cific diagnostic tool for patients with IMS.2 Neverthe-
less, findings of electrophysiologic studies in patients
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with IMS did not yield consistent results.2,6,7,19,21 In
the paper reported by Senanayake and Karalliedde, teta-
nic stimulation of the abductor pollicis brevis muscle
showed a marked fade at 20 Hz and 50 Hz, and there
was no post-tetanic facilitation.2 In contrast, De Bleecker
et al demonstrated early decrements at low frequencies
of stimulation (1–3 Hz) with normal series at 10, 20
and 50 Hz, or decrements at intermediate frequencies
(10–20Hz) with normal findings at both low and 50Hz
frequencies.6 A few days after poisoning, either mild
decrement–increment phenomenon at high frequencies
(20 or 50 Hz) or isolated increments (up to 220%) at
10 or 20 Hz were recorded. Neither increment nor
decrement after repetitive stimulation was shown in a
case reported by Sedgwick and Senanayake.19 In the
study reported by He et al, some patients had amplitude
decrements at frequencies of 10, 20 or 30 Hz, while 
2 patients did not show any decrements.7 Jayawardane
et al recently conducted a prospective serial repetitive
nerve stimulation study of 70 patients with organo-
phosphate insecticide poisoning.21 They found that
serial repetitive nerve stimulation findings correlated
with muscle power in 9 patients who developed classical
IMS. In the early phase of IMS, decrement–increment
pattern at 10–30Hz was detected. With clinical progres-
sion, decrement–increment pattern was noted at low
frequencies (1–3 Hz), which then changed to severe
decrements, mostly at high frequencies, among patients
with severe IMS. Because decrement–increment phe-
nomenon at intermediate and high frequencies were
found among patients manifesting muscle weakness
who did not develop classical IMS, the authors con-
cluded that IMS was probably a spectrum disorder
and neurophysiologic examinations might be useful
in predicting the development of IMS.
Management
IMS carries a high risk of death among patients with
respiratory failure. Therefore, prompt recognition of
the syndrome is the cornerstone of IMS management.
Treatment of IMS per se is mainly supportive,2,7,8,14,17
and there are no specific antidotes available for this de-
vastating syndrome. Nevertheless, because IMS gener-
ally concurs with severe organophosphate toxicity and
persistent inhibition of acetylcholinesterase, early ag-
gressive gastrointestinal decontamination, followed by
appropriate therapy of atropine and oximes, and prompt
institution of ventilatory support, should be helpful
in ameliorating the magnitude and/or the incidence
of IMS. For example, Chen, in a study of 286 patients
with organophosphate poisoning, demonstrated that
therapy with obidoxime, a more potent oxime compared
to pralidoxime, significantly decreased the incidence of
respiratory failure, the length of hospitalization, and
mortality.13
Repeated dose of fresh frozen plasma therapy has
been proposed in the treatment of IMS. Guven et al
found that frozen plasma therapy could prevent the
development of IMS and related mortality through
the restoration of plasma acetylcholinesterase.12 The
authors, however, did not explain how the change in
plasma acetylcholinesterase concentration could be
relevant to the function of the neuromuscular junc-
tions. Moreover, the study was not a randomized trial,
and the authors did not provide enough information
to determine whether the treatment effect was con-
founded or not. Similar results were found in a study
of 36 Chinese patients with IMS.22 Among 13 patients
who received whole blood transfusion of 400–800mL/
day for up to 5 days, only 1 patient died, while 7 out
of 23 patients without blood transfusion died.
Summary
IMS is a major cause of morbidity and mortality in
patients with acute organophosphate insecticide poi-
soning. Although IMS is well recognized as a disorder
of neuromuscular junctions, its exact etiology, inci-
dence, and risk factors are not clearly defined because
existing studies are largely small-scale case series and
do not employ a consistent and rigorous definition of
IMS. Without a clear understanding of the patho-
physiology of IMS, specific therapy is not available
and supportive measures remain the cornerstone in the
management of IMS. The prognosis of IMS, however,
is likely to be favorable if respiratory failure can be
promptly recognized and treated accordingly. Future
studies on IMS should focus on delineating the patho-
physiology of IMS and the identification of clinical
and/or laboratory predictors of IMS by employing
well-defined definitions of IMS.
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